DNTH
Dianthus Therapeutics, Inc.About DNTH
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
Company
- Headquarters
- New York, NY
- Employees
- 92 (2026)
- Listed
- Sep 12, 2023
- Exchange
- Nasdaq
- Website
- dianthustx.com
- SEC industry
- Pharmaceutical Preparations
- Cylvex sector
- Health Care · Pharmaceuticals
Pharmaceuticals
- Market cap #51 of 430
- P/B #106 of 396
Ranked highest first among stocks Cylvex covers.
- LLYEli Lilly and Company$1.26T+0.60%
- JNJJohnson & Johnson$665.3B+3.83%
- ABBVAbbVie Inc$520.9B+3.07%
- MRKMerck & Co Inc$370.9B+3.91%
- NVSNovartis AG$311.6B+3.60%
Financial summary
Related companies
About
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
From company filings and market data · Not investment advice
Price data
From daily bars
Financials
Consensus estimates
The information provided is for educational purposes only and does not constitute investment advice. Past performance does not guarantee future results.